StockNews.AI
AVDL
StockNews.AI
111 days

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7

1. AVDL will host a Q1 2025 financial update on May 7, 2025. 2. LUMRYZ™ is the first FDA-approved nighttime oxybate for narcolepsy. 3. The company aims to transform lives with innovative medications.

Earnings
+0.99%Current Return
VS
+1.32%S&P 500
$8.6104/30 08:06 AM EDTEvent Start
$8.69505/01 03:15 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial updates often indicate future growth potential, especially for AVDL's innovative products.

How important is it?

Financial updates reflect operational success and product performance, impacting investor sentiment.

Why Short Term?

The financial results call may quickly influence stock price due to immediate investor reactions.

Related Companies

VRTXNBIXHGEN
April 30, 2025 08:00 ET  | Source: Avadel Pharmaceuticals plc DUBLIN, Ireland, April 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Wednesday, May 7, 2025, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2025. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. About Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. For more information, please visit www.avadel.com. Investor Contact:Austin Murtagh Precision AQAustin.Murtagh@precisionAQ.com (212) 698-8687 Media Contact:Lesley StanleyReal Chemistrylestanley@realchemistry.com (609) 273-3162

Related News